Disulfiram, a specific gasdermin D inhibitor, mediates AAA suppression in part by inhibiting gasdermin D cleavage, which consequently diminishes the release of proaneurysmal mediators from macrophages and secretory SMCs in pore-dependent and/or -independent mechanisms. Here, GSDMD is linked to triple-A syndrome.